- Home
- STRO
STRO
Sutro Biopharma Inc.
as 05-30-2025 4:00pm EST
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 77.7M | IPO Year: | 2018 |
| Target Price: | $5.47 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $5.17 | Next Earning Date: | 05-08-2025 |
| Revenue: | $66,434,000 | Revenue Growth: | -56.88% |
| Revenue Growth (this year): | -9.42% | Revenue Growth (next year): | -16.37% |
Latest Sutro Biopharma Inc. News
STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
24 days ago
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
24 days ago
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
a month ago
Sutro Biopharma to Participate in Upcoming Investor Conferences
GlobeNewswire
a month ago
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
TipRanks
2 months ago
Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls
MT Newswires
2 months ago
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2
MT Newswires
2 months ago
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform
Compare STRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STRO Sutro Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.